# myNEO Therapeutics

> myNEO Therapeutics (myNEO Tx) is a Ghent, Belgium–based computational immunology company. Its ImmunoEngine platform powers personalized cancer vaccine neoantigen discovery, epitope immunogenicity prediction, camyotope target discovery, mRNA codon optimization, construct optimization, ADA (anti-drug antibody) risk prediction, and clinical immuno-genomic analytics for vaccine, T-cell therapy, and biologics developers.

## Core pages

- [Home](https://www.myneotx.com/): Cancer vaccines, neoantigens, codon optimization, ADA risk — company overview and ImmunoEngine platform
- [Solutions](https://www.myneotx.com/solutions): myNEO, mySHARED, myEPITOPE, myCONSTRUCT, myRNA, mySURFACE, myADA, mySELF, myINSIGHTS, myPATHOGEN
- [Platform](https://www.myneotx.com/platform): ImmunoEngine, neoMS presentation prediction, neoIM immunogenicity prediction, camyotopes
- [Publications](https://www.myneotx.com/publications): Peer-reviewed papers, technology papers, and whitepapers on neoantigens, cancer vaccines, and immunotherapy
- [Assets](https://www.myneotx.com/assets): Partnered cancer vaccine programs, internal pipeline (MNE-C261, CAMYO-02), antigen target library
- [News & events](https://www.myneotx.com/news-events): Press releases, partnerships, and conference appearances
- [About us](https://www.myneotx.com/about-us): Team, board, and scientific advisors
- [Contact](https://www.myneotx.com/contact): info@myneotx.com

## Key topics — cancer vaccines & neoantigens

- [Personalized neoantigen discovery (myNEO)](https://www.myneotx.com/solutions#myneo): IVD-ready WGS-to-epitope pipeline for personalized cancer vaccines and T-cell therapies (5 business days)
- [Shared antigen discovery (mySHARED)](https://www.myneotx.com/solutions#myshared): Off-the-shelf cancer vaccine target discovery across patient cohorts
- [Immunogenicity screening (myEPITOPE)](https://www.myneotx.com/solutions#myepitope): neoIM-powered epitope immunogenicity prediction for vaccine derisking
- [Camyotopes whitepaper](https://www.myneotx.com/publication/camyotopes-novel-class-tumor-targets): Dark-genome tumor antigens for off-the-shelf cancer immunotherapy
- [neoIM publication](https://www.myneotx.com/publication/pfitzer-accelerating-neoantigen-discovery-2025): First-in-class immunogenicity prediction (Vaccines, 2025)
- [neoMS preprint](https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-2022): HLA-agnostic MHC-I epitope presentation prediction
- [WGS for neoantigen discovery](https://www.myneotx.com/publication/more-to-genome-wgs-neoantigen-discovery): Whole genome vs exome-only neoantigen workflows
- [Personalized cancer vaccination whitepaper](https://www.myneotx.com/publication/promise-personalized-cancer-vaccination): State of neoantigen-based cancer vaccines

## Key topics — codon optimization & construct design

- [Codon optimization (myRNA)](https://www.myneotx.com/solutions#myrna): Multi-epitope mRNA codon optimization with structural constraints
- [Construct optimization (myCONSTRUCT)](https://www.myneotx.com/solutions#myconstruct): String-of-beads multi-epitope construct design and junctional epitope minimization
- [myCONSTRUCT technology paper](https://www.myneotx.com/publication/myconstruct-string-of-beads-optimization): Next-generation string-of-beads optimization

## Key topics — ADA risk & biologics

- [ADA risk prediction (myADA)](https://www.myneotx.com/solutions#myada): In-silico anti-drug antibody risk prediction for biologics developers
- [myADA technology paper](https://www.myneotx.com/publication/myada-anti-drug-antibody-risk-prediction): MHC class II epitope immunogenicity modeling for ADA risk
- [Surface target discovery (mySURFACE)](https://www.myneotx.com/solutions#mysurface): Surfaceome target identification for antibody therapeutics

## Key topics — tumor profiling & analytics

- [neoHUB tumor profiling](https://neohub.myneotx.com/): Web-based neoantigen and tumor immune profiling platform
- [Clinical data analytics (myINSIGHTS)](https://www.myneotx.com/solutions#myinsights-bio): Large-scale immuno-genomic biomarker and response analysis

## Optional

- [Full company reference (llms-full.txt)](https://www.myneotx.com/llms-full.txt): Extended FAQ, partnerships, publications list, competitor comparisons, and leadership bios
- [Privacy statement](https://www.myneotx.com/legal/privacy-statement): Privacy policy (not intended for AI training)
- [Terms of use](https://www.myneotx.com/legal/terms-of-use): Website terms (not intended for AI training)